Title : From petri dish to production - Navigating manufacturing challenges in probiotic scale up
Abstract:
Transitioning probiotics from lab-scale to commercial production demands careful strategies to overcome technical, regulatory, and economic barriers. Manufacturer of probiotics face scale up challenges like media sterilization, media cost, selecting suitable media, identifying contamination risks, inconsistent cell viability and meeting the regulatory requirements like Good Manufacturing Practice (GMP) standards, WHO guidelines, and regional regulations (FDA, EFSA, FSSAI, etc.) to ensure safety and efficacy. Addressing these challenges requires optimized fermentation, cost-effective media, and advanced processing techniques. Lab conditions allow precise control, but industrial fermenters introduce uneven temperature, oxygen gradients, and mixing issues that reduce yields and alter biomass production. Probiotic strains thriving in small batches at lab scale may underperform due to these factors, requiring process redesigns like optimized media or bioreactor tweaks. Downstream processes like centrifugation and drying exacerbate viability losses due to prolonged stresses and environmental sensitivities. Strain variability and fermentation inefficiencies cause unpredictable yields during scale-up. Stability of probiotics suffers from environmental sensitivities, with viability losses during drying, storage, and delivery; for instance, industrial processes can reduce cell counts significantly without protective measures. Scale-up of probiotic processes is preferably done in two stages. The first stage is a pilot plant (pilot scale) with 100–10,000 L fermenters and matched downstream equipment. Its purpose is to translate the lab-scale process into a realistic scaled-down version of the manufacturing process. The selected pilot scale is a judgment based on the size, availability, and cost of representative scaled-down equipment and required product sample sizes. The second stage of scale-up is a demonstration plant (demo scale) with 10 000–100 000 L fermenters and matched downstream. It serves to minimize the risk of a large capital investment in the full-scale manufacturing plant by further validating the process, the supply chain (from raw materials to commercial product application), and market demand. Contamination from unwanted microbes or allergens demands rigorous testing, which intensifies at scale. Ensuring probiotic viability through drying, storage, and delivery requires rigorous hygiene to prevent contamination, alongside sensory and dose consistency in products. Shelf-life stability further complicates matters, necessitating advanced packaging and real-time monitoring.
